Wird geladen...
Development of Photoonycholysis with Vandetanib Therapy
Vandetanib therapy is a novel once-daily oral multitargeted tyrosine kinase inhibitor, which is currently used in advanced or metastatic medullary thyroid cancer. Skin toxicities are among the most prevalent adverse events reported with this targeted therapy (e.g. acne-like rash, hand-foot skin reac...
Gespeichert in:
| Veröffentlicht in: | Skin Appendage Disord |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
S. Karger AG
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5264363/ https://ncbi.nlm.nih.gov/pubmed/28232923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452425 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|